Literature DB >> 19213079

Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro.

Steven W Warmann1, Sorin Armeanu, Heike Heigoldt, Peter Ruck, Reinhard Vonthein, Heike Heitmann, Guido Seitz, Marie-Luise Lemken, Michael Bitzer, Jörg Fuchs, Ulrich M Lauer.   

Abstract

BACKGROUND: Multidrug resistance is a key factor for the sobering outcome of relapsed and metastatic human hepatoblastoma (HB). Gene directed treatment approaches were recently identified as possible treatment options against advanced HB, in which standard chemotherapy regimens are partially insufficient. The aim of this study was to systematically analyze the effects of suicide gene therapy in three HB cell lines using a yeast-derived cytosine deaminase (YCD)-combined yeast uracil phosphoribosyltransferase (YUPRT)-based adenovirus-mediated gene transfer. PROCEDURE: YCD and YUPRT were fused to form the bifunctional suicide gene SuperCD. Adeonoviral vectors were used for transduction. Tumor cells transduced at MOI 50 were incubated with 5-fluorocytosine (5-FC) in ascending concentrations.
RESULTS: Transduction rates were 87.8% (+6.7) in the mixed HB cell line HUH6, 98.6% (+1.4) in the epithelial HB cell line HepT1 and 93.6% (+0.6) in the multifocal HB embryonal cell line HepT3, respectively. In HepT3 and HepT1 cells suicide gene therapy with SuperCD/5-FC was highly effective leading to HB cell damage far above those of application of the prodrug 5-FC only. In HUH6 cells the approach had no effect due to a lack in activity of the CMV promoter being employed for transcription of the SuperCD transgene.
CONCLUSION: Assuming employment of fully active promoters, the SuperCD/5-FC approach may serve as a potentially useful anti-tumor strategy against advanced HB. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19213079     DOI: 10.1002/pbc.21956

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  Current and future management strategies for relapsed or progressive hepatoblastoma.

Authors:  Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

2.  Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines.

Authors:  Carmen Eicher; Alexander Dewerth; Verena Ellerkamp; Joerg Fuchs; Sarah Schott; Sorin Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2013-02       Impact factor: 1.827

Review 3.  The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.

Authors:  Justus Lieber; Sorin Armeanu-Ebinger; Jörg Fuchs
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.